X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13632) 13632
Book Chapter (32) 32
Dissertation (17) 17
Publication (14) 14
Book / eBook (8) 8
Conference Proceeding (5) 5
Magazine Article (4) 4
Web Resource (4) 4
Newspaper Article (2) 2
Trade Publication Article (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8272) 8272
poly polymerase (5820) 5820
animals (5618) 5618
apoptosis (5109) 5109
poly polymerases - metabolism (4924) 4924
oncology (3494) 3494
apoptosis - drug effects (2904) 2904
mice (2848) 2848
cancer (2841) 2841
biochemistry & molecular biology (2748) 2748
poly polymerase inhibitors (2590) 2590
cell line, tumor (2557) 2557
female (2501) 2501
cell biology (2452) 2452
proteins (2089) 2089
male (2061) 2061
dna damage (2006) 2006
activation (1909) 1909
dna repair (1804) 1804
poly polymerase-1 (1704) 1704
expression (1526) 1526
enzyme inhibitors - pharmacology (1422) 1422
rats (1421) 1421
oxidative stress (1361) 1361
deoxyribonucleic acid--dna (1347) 1347
inhibition (1343) 1343
caspases - metabolism (1332) 1332
ribose (1291) 1291
antineoplastic agents - pharmacology (1267) 1267
cell death (1249) 1249
tumors (1228) 1228
pharmacology & pharmacy (1221) 1221
chemotherapy (1206) 1206
breast cancer (1170) 1170
research (1147) 1147
cell survival - drug effects (1142) 1142
caspase (1141) 1141
gene expression (1134) 1134
mutation (1118) 1118
cell line (1113) 1113
phosphorylation (1112) 1112
signal transduction (1112) 1112
cell cycle (1100) 1100
poly polymerases - genetics (1051) 1051
cells (1029) 1029
dna (1022) 1022
polymerase (1018) 1018
kinases (998) 998
cells, cultured (995) 995
multidisciplinary sciences (979) 979
cell proliferation - drug effects (974) 974
death (969) 969
caspase-3 (960) 960
analysis (956) 956
inhibitors (939) 939
caspase 3 - metabolism (928) 928
dose-response relationship, drug (914) 914
research article (906) 906
blotting, western (887) 887
dna-damage (879) 879
homologous recombination (865) 865
mitochondria (855) 855
parp (851) 851
poly (851) 851
repair (847) 847
cytotoxicity (833) 833
poly polymerase 1 (831) 831
caspase 3 (801) 801
medicine (800) 800
genetic aspects (789) 789
health aspects (789) 789
adenosine diphosphate (781) 781
cell-death (764) 764
monosaccharides (754) 754
sugars (749) 749
in-vitro (743) 743
tumor cells, cultured (740) 740
enzymes (738) 738
biology (733) 733
cancer therapies (729) 729
care and treatment (715) 715
flow cytometry (715) 715
ovarian cancer (715) 715
signal transduction - drug effects (715) 715
benzamides - pharmacology (707) 707
enzyme activation (703) 703
neurosciences (695) 695
cell proliferation (687) 687
apoptosis - physiology (680) 680
science (652) 652
reactive oxygen species - metabolism (641) 641
time factors (624) 624
protein (613) 613
inflammation (608) 608
proto-oncogene proteins c-bcl-2 - metabolism (596) 596
rodents (596) 596
poly polymerase inhibitors - pharmacology (589) 589
nf-kappa-b (588) 588
antineoplastic agents - therapeutic use (580) 580
mitochondria - metabolism (576) 576
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13577) 13577
Japanese (76) 76
Chinese (59) 59
French (48) 48
German (17) 17
Russian (17) 17
Korean (12) 12
Polish (7) 7
Hungarian (5) 5
Ukrainian (3) 3
Czech (2) 2
Spanish (2) 2
Hebrew (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of pharmacology and experimental therapeutics, ISSN 1521-0103, 2015, Volume 353, Issue 3, pp. 446 - 457
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 362, Issue 6414, pp. eaat8407 - 557
.... PARP inhibitors or genetic deletion of PARP-1 prevented pathologic α-syn toxicity. In a feed-forward loop, PAR converted pathologic α... 
STRAINS | MECHANISMS | PROTEIN | MULTIDISCIPLINARY SCIENCES | AGGREGATION | CELL-DEATH | Recombinant Proteins - metabolism | Parkinson Disease - pathology | Dopaminergic Neurons - pathology | Mice, Inbred C57BL | Poly (ADP-Ribose) Polymerase-1 - metabolism | Recombinant Proteins - genetics | Gene Knockout Techniques | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Mice, Knockout | Brain - metabolism | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Poly Adenosine Diphosphate Ribose - metabolism | Animals | Dopaminergic Neurons - metabolism | Cell Death | Brain - pathology | Benzimidazoles - pharmacology | Mice | Parkinson Disease - metabolism | alpha-Synuclein - genetics | Enzyme Activation | Nitric Oxide - metabolism | alpha-Synuclein - metabolism | Poly (ADP-Ribose) Polymerase-1 - genetics | Therapy | Parkinson's disease | Pathogenesis | Disorders | Cognitive ability | Nervous system | Cerebrospinal fluid | Rigidity | Mental depression | Proteins | Fibrillogenesis | Cell activation | Neurodegeneration | Autonomic nervous system | Neostriatum | Biocompatibility | Anxiety | Inhibition | Toxic diseases | Constipation | Movement disorders | Deoxyribonucleic acid--DNA | Neurodegenerative diseases | Mortality | Adenosine diphosphate | Pathology | Cell injury | Molecular modelling | Inhibitors | Nitric oxide | Biomarkers | Toxicity | DNA damage | Activation | Accumulation | Neurotoxicity | Clonal deletion | Feedforward | Phenotypes | Adenosine | Dopamine | Neurons | Poly(ADP-ribose) polymerase | Caspase | Axons | Sleep | Cell death | In vivo methods and tests | Apoptosis | Index Medicus
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9737, pp. 245 - 251
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 19, pp. 2193 - 2202
Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascular endothelial growth factor signaling by vascular... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Journal Article
Current Protein and Peptide Science, ISSN 1389-2037, 11/2016, Volume 17, Issue 7, pp. 668 - 682
Journal Article
Cancer science, ISSN 1347-9032, 2019, Volume 110, Issue 3, pp. 1064 - 1075
Poly(ADP‐ribose) polymerase (PARP) enzymes play an important role in repairing DNA damage and maintaining genomic stability... 
toxicity | pharmacokinetics | poly(ADP‐ribose) polymerase | fluzoparib | antitumor activity | poly(ADP-ribose) polymerase | DOWN-REGULATION | OVARIAN-CANCER | COMBINATION | TUMORS | MAINTENANCE THERAPY | OLAPARIB | ONCOLOGY | DOUBLE-BLIND | AGENTS | HOMOLOGOUS RECOMBINATION | PARP INHIBITORS | DNA Repair - drug effects | Apoptosis - drug effects | Humans | Rats | Clinical Trials as Topic | Xenograft Model Antitumor Assays - methods | Piperazines - pharmacology | Rats, Sprague-Dawley | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Poly(ADP-ribose) Polymerases - metabolism | Animals | DNA Breaks, Double-Stranded - drug effects | Mice, Nude | Cell Line, Tumor | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Clinical trials | DNA damage | Sugars | Monosaccharides | Cell proliferation | Homologous recombination | Cytotoxicity | Metastasis | Kinases | Cancer therapies | DNA repair | Stomach cancer | Defects | Ovarian cancer | Homologous recombination repair | Enzymatic activity | Ribose | Paclitaxel | Xenografts | Drug dosages | Deoxyribonucleic acid--DNA | Enzymes | Poly(ADP-ribose) polymerase | Breast cancer | FDA approval | Poly(ADP-ribose) Polymerase 1 | Antitumor activity | Hypoxia | Software | Apoptosis | Pharmaceuticals | Index Medicus | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2007, Volume 13, Issue 5, pp. 1383 - 1388
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that signals the presence of DNA damage by catalyzing the addition of ADP-ribose units to DNA, histones, and various DNA repair enzymes and by facilitating DNA repair... 
Clinical Repair | DNA Repair | PARP | POLY(ADP-RIBOSE) POLYMERASE | REPAIR | RADIOSENSITIZATION | ONCOLOGY | DNA-DAMAGE | DEPENDENT PROTEIN-KINASE | DOUBLE-STRAND BREAKS | POTENT INHIBITORS | PARP-1 | CELL-DEATH | TEMOZOLOMIDE | Poly(ADP-ribose) Polymerases - drug effects | Poly(ADP-ribose) Polymerases - metabolism | Animals | Humans | Enzyme Inhibitors - pharmacology | Antineoplastic Agents - pharmacology | Clinical Trials as Topic
Journal Article
Cancer science, ISSN 1347-9032, 2018, Volume 109, Issue 11, pp. 3383 - 3392
...‐directed therapies for other solid organ malignancies. Poly (ADP‐ribose) polymerase inhibitors (PARPi... 
lysine‐specific histone demethylase‐1A | poly (ADP‐ribose) polymerase inhibitor | immune checkpoint inhibitor | cancer stem cell | triple‐negative breast cancer | triple-negative breast cancer | lysine-specific histone demethylase-1A | poly (ADP-ribose) polymerase inhibitor | PLACEBO | PD-L1 EXPRESSION | OVARIAN-CANCER | CANCER STEM-CELLS | PARP INHIBITOR | DNA-DEMETHYLATING AGENTS | THERAPY | ONCOLOGY | METASTATIC BREAST-CANCER | DOUBLE-BLIND | RESISTANCE | Homologous Recombination - drug effects | Neoplastic Stem Cells - drug effects | Humans | Clinical Trials as Topic | Triple Negative Breast Neoplasms - drug therapy | B7-H1 Antigen - genetics | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Up-Regulation - drug effects | Triple Negative Breast Neoplasms - genetics | Neoplastic Stem Cells - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - metabolism | Immunotherapy | Female | Histone Deacetylase Inhibitors - pharmacology | Epigenesis, Genetic - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Gene Expression Regulation, Neoplastic - drug effects | Drug Resistance, Neoplasm - drug effects | Epigenetic inheritance | Lysine | Cell death | Stem cells | Sugars | Monosaccharides | Drugs | Histone deacetylase | Transcription factors | DNA damage | Homologous recombination | Cytotoxicity | Cancer therapies | DNA repair | Immunosuppressive agents | Ovarian cancer | Proteins | Epidermal growth factor | Antitumor agents | Ribose | Cell cycle | Deoxyribonucleic acid--DNA | Phenotypes | Breast cancer | Chemotherapy | Immunogenicity | Response rates | Epigenetics | Ligands | Tumors | Apoptosis | Review
Journal Article